Trials / Conditions / Recurrent Malignant Neoplasm

Recurrent Malignant Neoplasm

20 registered clinical trials studyying Recurrent Malignant Neoplasm — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy NCT04409314	University of California, San Francisco	—
Completed	Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America NCT04089488	AIDS Malignancy Consortium	—
Active Not Recruiting	Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Ca NCT03743649	M.D. Anderson Cancer Center	Phase 2 / Phase 3
Active Not Recruiting	Financial Distress in Advanced Cancer Patients NCT04053517	M.D. Anderson Cancer Center	—
Completed	Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and NCT03856060	M.D. Anderson Cancer Center	N/A
Completed	Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings NCT04186884	M.D. Anderson Cancer Center	—
Terminated	DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating P NCT03439085	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy NCT03525873	M.D. Anderson Cancer Center	Phase 3
Active Not Recruiting	Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recu NCT03021486	M.D. Anderson Cancer Center	Phase 2 / Phase 3
Completed	Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866	National Cancer Institute (NCI)	Phase 1
Completed	Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319	Mayo Clinic	EARLY_Phase 1
Active Not Recruiting	Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer NCT02491632	M.D. Anderson Cancer Center	Phase 2 / Phase 3
Completed	PCRC-Supported Legacy Intervention in Pediatric Palliative Care NCT04059393	Vanderbilt-Ingram Cancer Center	N/A
Active Not Recruiting	Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations i NCT02286687	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II) NCT02152254	M.D. Anderson Cancer Center	Phase 2
Recruiting	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Canc NCT01790152	Children's Oncology Group	—
Completed	Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers NCT01624766	M.D. Anderson Cancer Center	Phase 1
Completed	Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer NCT01582191	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434	M.D. Anderson Cancer Center	Phase 1
Completed	Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mu NCT01531361	M.D. Anderson Cancer Center	Phase 1